Key result
POLARx matches Arctic Front Advance with 100% acute PVI, but requires longer procedure times.
Why the study?
A novel cryoballoon single-shot device was recently designed, motivating a comparison of its efficacy, safety, and characteristics with the established system.
Does the POLARx cryoballoon system improve acute pulmonary vein isolation and procedural characteristics compared to the AFA system in patients with atrial fibrillation?
Observational (n=596)
No
Does the POLARx cryoballoon system improve acute pulmonary vein isolation and procedural characteristics compared to the AFA system in patients with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
The novel POLARx cryoballoon system is as effective and safe as the established Arctic Front Advance system for acute pulmonary vein isolation, with procedural differences partly reflecting the operators' learning curve.
Cryoballoon (CB)-guided pulmonary vein isolation (PVI) represents a cornerstone in the treatment of atrial fibrillation (AF). Recently, a novel balloon-guided single shot device (POLARx, Boston Scientific) was designed. Our study aimed to compare the efficacy, safety and characteristics of the novel CB system with the established one (Arctic Front Advance (Pro), AFA, Medtronic). A total number of 596 patients undergoing CB-guided ablation for AF were included. 65 patients (65.0 ± 11.6, 31% female) undergoing PVI with the POLARx were compared to a cohort of 531 consecutive patients (63.0 ± 27.9, 25% female) treated with AFA. Acute PVI was achieved in all patients (n = 596, 100%). Total procedure duration (POLARx 113.3 ± 23.2 min, AFA 100.9 ± 21.3 min; p < 0.001) and fluoroscopy time (POLARx 10.5 ± 5.9 min, AFA 4.8 ± 3.6 min; p < 0.001) were significantly longer in the POLARx group. The POLARx balloon achieved significantly lower nadir temperatures (POLARx −57.7 ± 0.9 °C, AFA −45.1 ± 2.6 °C; p < 0.001) and a significantly higher percentage of pulmonary veins successfully isolated with the first freeze (p = 0.027 *). One major complication occurred in the POLARx (2%) and three (1%) in the AFA group. Both ablation systems are comparably safe and effective. AF ablation utilizing the POLARx system is associated with longer procedure and fluoroscopy times as well as lower nadir temperatures.
No takes yet. Share an insight, caveat, or question.
Guckel et al. (2022) conducted an observational in Atrial Fibrillation (n=596). POLARx cryoballoon system vs. Arctic Front Advance (AFA) cryoballoon system was evaluated on Acute pulmonary vein isolation (PVI) (p=1.000). The POLARx and Arctic Front Advance cryoballoon systems both achieved 100% acute pulmonary vein isolation, though POLARx was associated with longer procedure times and lower nadir temperatures.
Synapse has enriched 10 related papers. Consider them for comparative context: